USA

Under the agreement, the companies will advance Sail’s lead programme, SAIL-0839, which is being developed to engineer CD4+ and CD8+ T-cells inside the body to treat immune-mediated diseases.

RushData aims to address these bottlenecks by bringing antibody expression, binding analysis and early developability profiling into a standardised workflow.

The approval makes Simtriyo the first norepinephrine, dopamine, serotonin reuptake inhibitor (NDSRI) for ADHD and gives Otsuka what Jefferies analysts described as its “next major CNS launch.”

The approval provides consumers with an additional non-prescription option for managing common types of temporary pain.

Lytenava contains bevacizumab, an anti-vascular endothelial growth factor (anti-VEGF) antibody that inhibits the growth of abnormal blood vessels that can damage the retina.

The agreements are nonexclusive and cover Aspen Pharmacare, Quality Chemical Industries and UCL Kenya in sub-Saharan Africa, as well as Aurobindo, Cipla, Emcure and Viatris in India.

The company plans to construct a new three-story, 145,000-square-foot facility for drug product manufacturing and packaging next to its existing operations.

Under the terms of the agreement, Lilly will pay US$6.75 per share in cash, representing a 40% premium over AtaiBeckley’s 30-day volume-weighted average share price.

Following the transaction, former Kira shareholders will own nearly 50% of the combined company, new private financing investors will hold slightly more than 43%, and existing Jasper shareholders will retain almost 7%.

Unlike traditional robotic-arm platforms, Mako RPS delivers a handheld robotic experience while leveraging the company’s expertise in robotics and surgical power tools.